SIRPant Immunotherapeutics Inc
Wednesday, June 05, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 1
SIRPant Immunotherapeutics Inc. is a clinical stage company focused on the development of novel autologous macrophage cell therapy for treatment of aggressive tumors with unmet medical needs.
SIRPant employs first-in-class macrophage-based cellular immunotherapy to drive robust and lasting immune responses that leverage downstream polyclonal killer T cells and polyclonal antibodies to target the tumor neo-antigens. In contrast to other forms of cellular immunotherapy, SIRPant utilizes a multi-pronged approach that engages multiple effector pathways simultaneously to elicit immunological response to treat cancer in a completely novel way.
The company’s lead candidate is an autologous SIRPα-low activated macrophage therapy for the treatment of non-Hodgkin’s Lymphoma (NHL), under which the company intends to dose the first patient in Q4 2023. In Q4 2023 SIRPant filed a second IND for solid tumors.
Company Website:
http://www.sirpantimmunotx.com
Lead Product in Development:
SIRPant-M™ Autologous Sirpα-low Activated Macrophage
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Two
Company HQ City
Hummelstown
Company HQ State
PA
Company HQ Country
United States
CEO/Top Company Official
Robert J Towarnicki
Development Phase of Primary Product
Phase I
Primary Speaker